<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631474</url>
  </required_header>
  <id_info>
    <org_study_id>171-7151-201</org_study_id>
    <nct_id>NCT01631474</nct_id>
  </id_info>
  <brief_title>A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intrepid Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intrepid Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CB-03-01 is being developed for the topical treatment of acne vulgaris, an androgen-dependent&#xD;
      skin disorder. The purpose of this study is to compare the safety and efficacy of multiple&#xD;
      concentrations of CB-03-01 to vehicle in the treatment of acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA) &quot;Success&quot; - Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Count and percentage of subjects achieving success in each treatment group at Week 12 using the dichotomized IGA with success defined as a score of &quot;clear&quot; or &quot;almost clear&quot; (IGA Score of 0 or 1) and a two or more grade improvement from Baseline using a five-point scale (0=clear to 4=severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory and Non-Inflammatory Lesion Counts - Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 12.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and Non-Inflammatory Lesion Counts - Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Lesion Counts - Weeks 8 and 12</measure>
    <time_frame>Week 8 and Week 12</time_frame>
    <description>Percent change from Baseline in lesion counts (inflammatory and noninflammatory) in each treatment group at Weeks 8 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA &quot;Success&quot; - Week 8</measure>
    <time_frame>Baseline and Week 8</time_frame>
    <description>Count and percentage of subjects achieving success per the IGA in each treatment group at Week 8 (&quot;success&quot; as defined in the primary endpoints section).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGA &quot;Clear&quot; or &quot;Almost Clear&quot; - Weeks 4, 8 and 12</measure>
    <time_frame>Weeks 4, 8, and 12</time_frame>
    <description>Count and percentage of subjects who are &quot;clear&quot; or &quot;almost clear&quot; (IGA Grade 0 or 1) in each treatment group at Weeks 4, 8 and 12.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">363</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Low-dose active, BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose of CB-03-01, 0.1% applied twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium-dose active, BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medium dose of CB-03-01, 0.5% applied twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose active, QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of CB-03-01, 1% applied once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose active, BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose of CB-03-01, 1% applied twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle, QD or BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>vehicle cream, applied once or twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-03-01</intervention_name>
    <description>Topical cream, applied once a day</description>
    <arm_group_label>High-dose active, QD</arm_group_label>
    <other_name>clascoterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Topical cream, applied once or twice a day</description>
    <arm_group_label>Vehicle, QD or BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CB-03-01</intervention_name>
    <description>Topical cream, applied twice a day</description>
    <arm_group_label>High-dose active, BID</arm_group_label>
    <arm_group_label>Low-dose active, BID</arm_group_label>
    <arm_group_label>Medium-dose active, BID</arm_group_label>
    <other_name>clascoterone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is male or non-pregnant female. Females must be post-menopausal, surgically&#xD;
             sterile or using highly effective birth control methods.&#xD;
&#xD;
          -  Subject has provided written and verbal informed consent/assent.&#xD;
&#xD;
          -  Subject has facial acne vulgaris (including the nose).&#xD;
&#xD;
          -  Subject is willing to comply with study instructions and return to the clinic for&#xD;
             required visits.&#xD;
&#xD;
          -  Subject has used the same type and brand of make-up, other facial products (including&#xD;
             cleanser) and hair products (e.g., shampoo, gel, hair spray, mousse, etc.) for at&#xD;
             least one month prior to the study start and agrees to continue his/her other general&#xD;
             skin and hair care products and regimen for the entire study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.&#xD;
&#xD;
          -  Subject is currently enrolled in an investigational drug or device study.&#xD;
&#xD;
          -  Subject has received an investigational drug or been treated with an investigational&#xD;
             device within 30 days prior to the study start.&#xD;
&#xD;
          -  Subject has the need or plans to be exposed to artificial tanning devices or excessive&#xD;
             sunlight during the trial&#xD;
&#xD;
          -  Subject has used any of the following topical anti-acne preparations or procedures on&#xD;
             the face:&#xD;
&#xD;
               -  Topical anti-acne treatments including but not limited to over-the-counter acne&#xD;
                  cleaners or treatments, benzoyl peroxide, antibiotics, azelaic acid, sulfa based&#xD;
                  products, corticosteroids and salicylic acid within two weeks of the initiation&#xD;
                  of treatment.&#xD;
&#xD;
               -  Retinoids, including tazarotene, adapalene, tretinoin, within four weeks of the&#xD;
                  initiation of treatment.&#xD;
&#xD;
               -  Light treatments, microdermabrasion or chemical peels within eight weeks of the&#xD;
                  initiation of treatment.&#xD;
&#xD;
          -  Subject has used the following systemic anti-acne medications:&#xD;
&#xD;
               -  Corticosteroids (including intramuscular and intralesional injections) within&#xD;
                  four weeks of the initiation of treatment. Inhaled, intranasal or ocular&#xD;
                  corticosteroids are allowed if use is stable (stable use is defined as dose and&#xD;
                  frequency unchanged for at least four weeks prior to the initiation of&#xD;
                  treatment).&#xD;
&#xD;
               -  Antibiotics within four weeks of the initiation of treatment with the exception&#xD;
                  of five days or less of antibiotic therapy during this period, but with no&#xD;
                  antibiotics use permitted within one week prior to the initiation of treatment.&#xD;
&#xD;
               -  Spironolactone within eight weeks of the initiation of treatment with the&#xD;
                  exception of five days or less of spironolactone therapy during this period, but&#xD;
                  with no spironolactone use permitted within one week prior to the initiation of&#xD;
                  treatment.&#xD;
&#xD;
               -  Retinoid therapy within six months of the initiation of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R&amp;D Cassiopea</last_name>
    <role>Study Director</role>
    <affiliation>Cassiopea S.p.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Research Associates</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research - US, LLC</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gwinnett Clinical Research Center, Inc.</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Clinical Trials Center</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marina I. Peredo, M.D., PC</name>
      <address>
        <city>Smithtown</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center - Dept. of Dermatology</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J &amp; S Studies</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Houston Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 27, 2012</study_first_submitted>
  <study_first_submitted_qc>June 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <results_first_submitted>September 23, 2020</results_first_submitted>
  <results_first_submitted_qc>October 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 16, 2020</results_first_posted>
  <disposition_first_submitted>March 27, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 27, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 16, 2015</disposition_first_posted>
  <last_update_submitted>October 22, 2020</last_update_submitted>
  <last_update_submitted_qc>October 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acne</keyword>
  <keyword>anti-androgen</keyword>
  <keyword>clascoterone</keyword>
  <keyword>cassiopea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Low-dose Active, BID</title>
          <description>low dose of CB-03-01, 0.1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
        </group>
        <group group_id="P2">
          <title>Medium-dose Active, BID</title>
          <description>medium dose of CB-03-01, 0.5% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
        </group>
        <group group_id="P3">
          <title>High-dose Active, QD</title>
          <description>high dose of CB-03-01, 1% applied once a day&#xD;
CB-03-01: Topical cream, applied once a day</description>
        </group>
        <group group_id="P4">
          <title>High-dose Active, BID</title>
          <description>high dose of CB-03-01, 1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
        </group>
        <group group_id="P5">
          <title>Vehicle, QD or BID</title>
          <description>vehicle cream, applied once or twice a day&#xD;
Vehicle: Topical cream, applied once or twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="70"/>
                <participants group_id="P5" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="61"/>
                <participants group_id="P4" count="59"/>
                <participants group_id="P5" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT Population. The ITT population included all subjects enrolled in the study who were randomized and dispensed test article.</population>
      <group_list>
        <group group_id="B1">
          <title>Low-dose Active, BID</title>
          <description>low dose of CB-03-01, 0.1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
        </group>
        <group group_id="B2">
          <title>Medium-dose Active, BID</title>
          <description>medium dose of CB-03-01, 0.5% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
        </group>
        <group group_id="B3">
          <title>High-dose Active, QD</title>
          <description>high dose of CB-03-01, 1% applied once a day&#xD;
CB-03-01: Topical cream, applied once a day</description>
        </group>
        <group group_id="B4">
          <title>High-dose Active, BID</title>
          <description>high dose of CB-03-01, 1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
        </group>
        <group group_id="B5">
          <title>Vehicle, QD or BID</title>
          <description>vehicle cream, applied once or twice a day&#xD;
Vehicle: Topical cream, applied once or twice a day</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="70"/>
            <count group_id="B4" value="70"/>
            <count group_id="B5" value="75"/>
            <count group_id="B6" value="363"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.8" spread="5.77"/>
                    <measurement group_id="B2" value="20.4" spread="6.31"/>
                    <measurement group_id="B3" value="18.3" spread="6.14"/>
                    <measurement group_id="B4" value="21.0" spread="6.22"/>
                    <measurement group_id="B5" value="19.2" spread="5.25"/>
                    <measurement group_id="B6" value="19.7" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="43"/>
                    <measurement group_id="B6" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="62"/>
                    <measurement group_id="B6" value="287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="257"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline IGA</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 - Clear</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 - Almost clear</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 - Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 - Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="53"/>
                    <measurement group_id="B6" value="247"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 - Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline lesions counts</title>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.9" lower_limit="20" upper_limit="74"/>
                    <measurement group_id="B2" value="29.0" lower_limit="20" upper_limit="74"/>
                    <measurement group_id="B3" value="31.9" lower_limit="20" upper_limit="72"/>
                    <measurement group_id="B4" value="28.6" lower_limit="20" upper_limit="63"/>
                    <measurement group_id="B5" value="30.5" lower_limit="20" upper_limit="75"/>
                    <measurement group_id="B6" value="30.0" lower_limit="20" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" lower_limit="21" upper_limit="99"/>
                    <measurement group_id="B2" value="44.5" lower_limit="21" upper_limit="98"/>
                    <measurement group_id="B3" value="46.7" lower_limit="21" upper_limit="91"/>
                    <measurement group_id="B4" value="47.2" lower_limit="20" upper_limit="98"/>
                    <measurement group_id="B5" value="43.9" lower_limit="20" upper_limit="99"/>
                    <measurement group_id="B6" value="45.2" lower_limit="20" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Investigator's Global Assessment (IGA) &quot;Success&quot; - Week 12</title>
        <description>Count and percentage of subjects achieving success in each treatment group at Week 12 using the dichotomized IGA with success defined as a score of &quot;clear&quot; or &quot;almost clear&quot; (IGA Score of 0 or 1) and a two or more grade improvement from Baseline using a five-point scale (0=clear to 4=severe).</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Per-Protocol Population, defined as a subset of the ITT population and included those subjects that met eligibility criteria, completed the end-of-study visit, and applied at least 80% of the expected treatment applications.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Active, BID</title>
            <description>low dose of CB-03-01, 0.1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O2">
            <title>Medium-dose Active, BID</title>
            <description>medium dose of CB-03-01, 0.5% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O3">
            <title>High-dose Active, QD</title>
            <description>high dose of CB-03-01, 1% applied once a day&#xD;
CB-03-01: Topical cream, applied once a day</description>
          </group>
          <group group_id="O4">
            <title>High-dose Active, BID</title>
            <description>high dose of CB-03-01, 1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, QD or BID</title>
            <description>vehicle cream, applied once or twice a day&#xD;
Vehicle: Topical cream, applied once or twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Global Assessment (IGA) &quot;Success&quot; - Week 12</title>
          <description>Count and percentage of subjects achieving success in each treatment group at Week 12 using the dichotomized IGA with success defined as a score of &quot;clear&quot; or &quot;almost clear&quot; (IGA Score of 0 or 1) and a two or more grade improvement from Baseline using a five-point scale (0=clear to 4=severe).</description>
          <population>Per-Protocol Population, defined as a subset of the ITT population and included those subjects that met eligibility criteria, completed the end-of-study visit, and applied at least 80% of the expected treatment applications.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Inflammatory and Non-Inflammatory Lesion Counts - Week 12</title>
        <description>Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 12.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Active, BID</title>
            <description>low dose of CB-03-01, 0.1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O2">
            <title>Medium-dose Active, BID</title>
            <description>medium dose of CB-03-01, 0.5% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O3">
            <title>High-dose Active, QD</title>
            <description>high dose of CB-03-01, 1% applied once a day&#xD;
CB-03-01: Topical cream, applied once a day</description>
          </group>
          <group group_id="O4">
            <title>High-dose Active, BID</title>
            <description>high dose of CB-03-01, 1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, QD or BID</title>
            <description>vehicle cream, applied once or twice a day&#xD;
Vehicle: Topical cream, applied once or twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory and Non-Inflammatory Lesion Counts - Week 12</title>
          <description>Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 12.</description>
          <population>Per protocol population.</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" spread="14.63"/>
                    <measurement group_id="O2" value="-5.8" spread="11.99"/>
                    <measurement group_id="O3" value="-10.1" spread="12.53"/>
                    <measurement group_id="O4" value="-12.3" spread="14.43"/>
                    <measurement group_id="O5" value="-9.1" spread="13.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="18.16"/>
                    <measurement group_id="O2" value="-6.1" spread="29.22"/>
                    <measurement group_id="O3" value="-8.4" spread="21.55"/>
                    <measurement group_id="O4" value="-15.5" spread="20.48"/>
                    <measurement group_id="O5" value="-6.7" spread="19.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Inflammatory and Non-Inflammatory Lesion Counts - Week 8</title>
        <description>Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 8.</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Active, BID</title>
            <description>low dose of CB-03-01, 0.1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O2">
            <title>Medium-dose Active, BID</title>
            <description>medium dose of CB-03-01, 0.5% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O3">
            <title>High-dose Active, QD</title>
            <description>high dose of CB-03-01, 1% applied once a day&#xD;
CB-03-01: Topical cream, applied once a day</description>
          </group>
          <group group_id="O4">
            <title>High-dose Active, BID</title>
            <description>high dose of CB-03-01, 1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, QD or BID</title>
            <description>vehicle cream, applied once or twice a day&#xD;
Vehicle: Topical cream, applied once or twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Inflammatory and Non-Inflammatory Lesion Counts - Week 8</title>
          <description>Absolute change from Baseline in inflammatory and non-inflammatory lesion counts in each treatment group at Week 8.</description>
          <population>Per protocol population</population>
          <units>lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="8.84"/>
                    <measurement group_id="O2" value="-7.2" spread="12.03"/>
                    <measurement group_id="O3" value="-7.2" spread="17.21"/>
                    <measurement group_id="O4" value="-11.5" spread="11.19"/>
                    <measurement group_id="O5" value="-11.3" spread="12.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.0" spread="13.76"/>
                    <measurement group_id="O2" value="-6.7" spread="16.33"/>
                    <measurement group_id="O3" value="-3.2" spread="37.01"/>
                    <measurement group_id="O4" value="-13.6" spread="17.99"/>
                    <measurement group_id="O5" value="-8.3" spread="17.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Lesion Counts - Weeks 8 and 12</title>
        <description>Percent change from Baseline in lesion counts (inflammatory and noninflammatory) in each treatment group at Weeks 8 and 12.</description>
        <time_frame>Week 8 and Week 12</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Active, BID</title>
            <description>low dose of CB-03-01, 0.1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O2">
            <title>Medium-dose Active, BID</title>
            <description>medium dose of CB-03-01, 0.5% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O3">
            <title>High-dose Active, QD</title>
            <description>high dose of CB-03-01, 1% applied once a day&#xD;
CB-03-01: Topical cream, applied once a day</description>
          </group>
          <group group_id="O4">
            <title>High-dose Active, BID</title>
            <description>high dose of CB-03-01, 1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, QD or BID</title>
            <description>vehicle cream, applied once or twice a day&#xD;
Vehicle: Topical cream, applied once or twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Lesion Counts - Weeks 8 and 12</title>
          <description>Percent change from Baseline in lesion counts (inflammatory and noninflammatory) in each treatment group at Weeks 8 and 12.</description>
          <population>Per protocol population</population>
          <units>percentage of change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inflammatory lesions (Week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-40.6" spread="28.20"/>
                    <measurement group_id="O2" value="-26.6" spread="37.35"/>
                    <measurement group_id="O3" value="-27.5" spread="41.44"/>
                    <measurement group_id="O4" value="-41.1" spread="36.54"/>
                    <measurement group_id="O5" value="-36.0" spread="35.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory lesions (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.8" spread="50.78"/>
                    <measurement group_id="O2" value="-21.3" spread="45.33"/>
                    <measurement group_id="O3" value="-32.5" spread="35.51"/>
                    <measurement group_id="O4" value="-41.8" spread="52.25"/>
                    <measurement group_id="O5" value="-28.4" spread="41.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-inflammatory lesions (Week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.3" spread="34.50"/>
                    <measurement group_id="O2" value="-19.5" spread="36.49"/>
                    <measurement group_id="O3" value="-10.5" spread="57.13"/>
                    <measurement group_id="O4" value="-33.5" spread="39.26"/>
                    <measurement group_id="O5" value="-24.3" spread="43.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-inflammatory lesions (Week 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.3" spread="38.69"/>
                    <measurement group_id="O2" value="-16.9" spread="55.66"/>
                    <measurement group_id="O3" value="-19.5" spread="40.75"/>
                    <measurement group_id="O4" value="-34.1" spread="46.95"/>
                    <measurement group_id="O5" value="-19.5" spread="47.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IGA &quot;Success&quot; - Week 8</title>
        <description>Count and percentage of subjects achieving success per the IGA in each treatment group at Week 8 (&quot;success&quot; as defined in the primary endpoints section).</description>
        <time_frame>Baseline and Week 8</time_frame>
        <population>Per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Active, BID</title>
            <description>low dose of CB-03-01, 0.1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O2">
            <title>Medium-dose Active, BID</title>
            <description>medium dose of CB-03-01, 0.5% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O3">
            <title>High-dose Active, QD</title>
            <description>high dose of CB-03-01, 1% applied once a day&#xD;
CB-03-01: Topical cream, applied once a day</description>
          </group>
          <group group_id="O4">
            <title>High-dose Active, BID</title>
            <description>high dose of CB-03-01, 1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, QD or BID</title>
            <description>vehicle cream, applied once or twice a day&#xD;
Vehicle: Topical cream, applied once or twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>IGA &quot;Success&quot; - Week 8</title>
          <description>Count and percentage of subjects achieving success per the IGA in each treatment group at Week 8 (&quot;success&quot; as defined in the primary endpoints section).</description>
          <population>Per protocol population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IGA &quot;Clear&quot; or &quot;Almost Clear&quot; - Weeks 4, 8 and 12</title>
        <description>Count and percentage of subjects who are &quot;clear&quot; or &quot;almost clear&quot; (IGA Grade 0 or 1) in each treatment group at Weeks 4, 8 and 12.</description>
        <time_frame>Weeks 4, 8, and 12</time_frame>
        <population>Per protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Low-dose Active, BID</title>
            <description>low dose of CB-03-01, 0.1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O2">
            <title>Medium-dose Active, BID</title>
            <description>medium dose of CB-03-01, 0.5% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O3">
            <title>High-dose Active, QD</title>
            <description>high dose of CB-03-01, 1% applied once a day&#xD;
CB-03-01: Topical cream, applied once a day</description>
          </group>
          <group group_id="O4">
            <title>High-dose Active, BID</title>
            <description>high dose of CB-03-01, 1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
          </group>
          <group group_id="O5">
            <title>Vehicle, QD or BID</title>
            <description>vehicle cream, applied once or twice a day&#xD;
Vehicle: Topical cream, applied once or twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>IGA &quot;Clear&quot; or &quot;Almost Clear&quot; - Weeks 4, 8 and 12</title>
          <description>Count and percentage of subjects who are &quot;clear&quot; or &quot;almost clear&quot; (IGA Grade 0 or 1) in each treatment group at Weeks 4, 8 and 12.</description>
          <population>Per protocol population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="55"/>
                <count group_id="O5" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="57"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="62"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="57"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="52"/>
                    <count group_id="O4" value="55"/>
                    <count group_id="O5" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from screening visit, Baseline (Day 1) and up to Week 12/early termination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Low-dose Active, BID</title>
          <description>low dose of CB-03-01, 0.1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
        </group>
        <group group_id="E2">
          <title>Medium-dose Active, BID</title>
          <description>medium dose of CB-03-01, 0.5% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
        </group>
        <group group_id="E3">
          <title>High-dose Active, QD</title>
          <description>high dose of CB-03-01, 1% applied once a day&#xD;
CB-03-01: Topical cream, applied once a day</description>
        </group>
        <group group_id="E4">
          <title>High-dose Active, BID</title>
          <description>high dose of CB-03-01, 1% applied twice a day&#xD;
CB-03-01: Topical cream, applied twice a day</description>
        </group>
        <group group_id="E5">
          <title>Vehicle, QD or BID</title>
          <description>vehicle cream, applied once or twice a day&#xD;
Vehicle: Topical cream, applied once or twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="72"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="76"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="72"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 18 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 60 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cassiopea R&amp;D</name_or_title>
      <organization>Cassiopea, SpA</organization>
      <phone>+39 02 868 911 24</phone>
      <email>r&amp;d@cassiopea.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

